Literature DB >> 24515298

Gynecomastia in subjects with sexual dysfunction.

E Maseroli1, G Rastrelli, G Corona, V Boddi, A M L Amato, E Mannucci, G Forti, M Maggi.   

Abstract

PURPOSE: To analyze possible relationships between gynecomastia and clinical and biochemical parameters in a large cohort of subjects with sexual dysfunction (SD).
METHODS: A consecutive series of 4,023 men attending our Outpatient Clinic for SD was retrospectively studied.
RESULTS: After excluding Klinefelter's syndrome patients, the prevalence of gynecomastia was 3.1 %. Subjects with gynecomastia had significantly lower testosterone (T) levels; the association retained statistical significance after adjusting for age and life-style. However, only 33.3 % of subjects with gynecomastia were hypogonadal. Gynecomastia was associated with delayed puberty, history of testicular or hepatic diseases, as well as cannabis abuse. Patients with gynecomastia more frequently reported sexual complaints, such as severe erectile dysfunction [odds ratio (OR) = 2.19 (1.26-3.86), p = 0.006], lower sexual desire and intercourse frequency [OR = 1.23 (1.06-1.58) and OR = 1.84 (1.22-2.78), respectively; both p < 0.05], orgasm difficulties [OR = 0.49 (0.28-0.83), p = 0.008], delayed ejaculation and lower ejaculate volume [OR = 1.89 (1.10-3.26) and OR = 1.51 (1.23-1.86), respectively; both p < 0.05]. Gynecomastia was also positively associated with severe obesity, lower testis volume and LH, and negatively with prostate-specific antigen levels. The further adjustment for T did not affect these results, except for obesity. After introducing body mass index as a further covariate, all the associations retained statistical significance, except for delayed ejaculation and ANDROTEST score. When considering gynecomastia severity, we found a step-wise, T-independent, decrease and increase of testis volume and LH, respectively. Gynecomastia was also associated with the use of several drugs in almost 40 % of our patients.
CONCLUSION: Gynecomastia is a rare condition in subjects with SD, and could indicate a testosterone deficiency that deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24515298     DOI: 10.1007/s40618-014-0055-z

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  46 in total

1.  Gynaecomastia associated with proton pump inhibitors: a case series from the Spanish Pharmacovigilance System.

Authors:  Alfonso Carvajal; Diego Macias; Angélica Gutiérrez; Sara Ortega; María Sáinz; Luis H Martín Arias; Alfonso Velasco
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 2.  Drug-induced gynecomastia.

Authors:  John D Bowman; Hyunah Kim; Juan J Bustamante
Journal:  Pharmacotherapy       Date:  2012-11-16       Impact factor: 4.705

Review 3.  Gynecomastia: physiopathology, evaluation and treatment.

Authors:  Alfredo Carlos Simões Dornellas de Barros; Marcelo de Castro Moura Sampaio
Journal:  Sao Paulo Med J       Date:  2012       Impact factor: 1.044

Review 4.  Aromatase and gynecomastia.

Authors:  G D Braunstein
Journal:  Endocr Relat Cancer       Date:  1999-06       Impact factor: 5.678

5.  Serum prolactin levels in patients with gynecomastia.

Authors:  R W Turkington
Journal:  J Clin Endocrinol Metab       Date:  1972-01       Impact factor: 5.958

6.  Perceived ejaculate volume reduction in patients with erectile dysfunction: psychobiologic correlates.

Authors:  Giovanni Corona; Valentina Boddi; Mauro Gacci; Alessandra Sforza; Gianni Forti; Edoardo Mannucci; Mario Maggi
Journal:  J Androl       Date:  2010-08-12

Review 7.  Hormonal causes of male sexual dysfunctions and their management (hyperprolactinemia, thyroid disorders, GH disorders, and DHEA).

Authors:  Mario Maggi; Jaques Buvat; Giovanni Corona; André Guay; Luiz Otavio Torres
Journal:  J Sex Med       Date:  2012-04-23       Impact factor: 3.802

8.  Gynecomastia in a hospitalized male population.

Authors:  C B Niewoehner; F Q Nuttal
Journal:  Am J Med       Date:  1984-10       Impact factor: 4.965

Review 9.  The hormonal control of ejaculation.

Authors:  Giovanni Corona; Emmanuele A Jannini; Linda Vignozzi; Giulia Rastrelli; Mario Maggi
Journal:  Nat Rev Urol       Date:  2012-08-07       Impact factor: 14.432

Review 10.  Clinical review: Klinefelter syndrome--a clinical update.

Authors:  Kristian A Groth; Anne Skakkebæk; Christian Høst; Claus Højbjerg Gravholt; Anders Bojesen
Journal:  J Clin Endocrinol Metab       Date:  2012-11-01       Impact factor: 5.958

View more
  3 in total

1.  How to define hypogonadism? Results from a population of men consulting for sexual dysfunction.

Authors:  G Rastrelli; G Corona; M Tarocchi; E Mannucci; M Maggi
Journal:  J Endocrinol Invest       Date:  2016-01-05       Impact factor: 4.256

Review 2.  Klinefelter syndrome (KS): genetics, clinical phenotype and hypogonadism.

Authors:  M Bonomi; V Rochira; D Pasquali; G Balercia; E A Jannini; A Ferlin
Journal:  J Endocrinol Invest       Date:  2016-09-19       Impact factor: 4.256

Review 3.  Consequences of Anabolic-Androgenic Steroid Abuse in Males; Sexual and Reproductive Perspective.

Authors:  Giovanni Corona; Giulia Rastrelli; Sara Marchiani; Sandra Filippi; Annamaria Morelli; Erica Sarchielli; Alessandra Sforza; Linda Vignozzi; Mario Maggi
Journal:  World J Mens Health       Date:  2021-06-01       Impact factor: 5.400

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.